Leana Wen Sells 1,700 Shares of Glaukos (NYSE:GKOS) Stock
by Jessica Moore · The Cerbat GemGlaukos Corporation (NYSE:GKOS – Get Free Report) Director Leana Wen sold 1,700 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the transaction, the director owned 19,739 shares in the company, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Glaukos Stock Down 3.0%
Glaukos stock traded down $4.24 during mid-day trading on Monday, reaching $135.98. The stock had a trading volume of 942,743 shares, compared to its average volume of 790,624. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of -41.46 and a beta of 0.94. The company has a 50-day moving average price of $114.02 and a two-hundred day moving average price of $108.01. Glaukos Corporation has a one year low of $73.16 and a one year high of $146.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. Glaukos’s revenue was up 41.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.22) EPS. On average, analysts expect that Glaukos Corporation will post -0.6 EPS for the current fiscal year.
Hedge Funds Weigh In On Glaukos
Hedge funds and other institutional investors have recently bought and sold shares of the stock. AustralianSuper Pty Ltd lifted its stake in Glaukos by 10.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after acquiring an additional 43,750 shares during the period. JPMorgan Chase & Co. lifted its stake in Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares during the period. SG Americas Securities LLC lifted its stake in Glaukos by 460.8% during the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after acquiring an additional 49,492 shares during the period. TD Asset Management Inc bought a new position in shares of Glaukos in the 3rd quarter worth approximately $1,157,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Glaukos by 32.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after purchasing an additional 87,781 shares during the period. Institutional investors own 99.04% of the company’s stock.
Wall Street Analysts Forecast Growth
GKOS has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their price target on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday. Needham & Company LLC upped their target price on shares of Glaukos from $127.00 to $136.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company upped their target price on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, BTIG Research upped their target price on shares of Glaukos from $131.00 to $141.00 and gave the company a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $138.85.
Check Out Our Latest Research Report on Glaukos
Glaukos Company Profile
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.